Do I understand what you are alluding to Pharma -
The 10 March presentation says China will represent 40% of revenue in FY2023 and that total revenue is projected then to be $25m (p13). Thus the projected FY2023 revenue from China would be $10m.
The 3 May presentation now says China will represent 30% of FY2023 revenue.
That would allow two possibilities. Either the projected FY2023 China revenue has now reduced by 25% to $7.5m or, if China is still projected as $10m, the total projected revenue has increased to $33.3m for FY2023.
So it seems that this could be a glass-half-full or glass-half-empty choice for us shareholders.
I note that the figure Taurean7 has used in the analysis is $19.2m revenue for FY2023 which is conservative relative to both of these.
Time to toss a coin or do you think the new China license and Lyramid activity is seen as increasing the projected $25m?
poorinvestor
- Forums
- ASX - By Stock
- AN1
- An Evaluation of CDY Going Forward
An Evaluation of CDY Going Forward, page-17
-
-
- There are more pages in this discussion • 104 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AN1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
AN1 (ASX) Chart |
Day chart unavailable
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, Chief Executive Officer
Paul Long
Chief Executive Officer
SPONSORED BY The Market Online